Jun 28, 2022 / 02:00PM GMT
Operator
Ladies and gentlemen, welcome to the webcast on the positive top line results of Phase III ERADICATE study in SAB. I'm Alice, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to David Veitch, Chief Executive Officer. Please go ahead, sir.
David Veitch - Basilea Pharmaceutica AG - CEO
Thank you. Hello. I'd like to welcome you to our conference call and webcast, reviewing our Phase III ceftobiprole data and the next steps and we will also highlight our progress with the implementation of our strategy to become a leading global anti-infectives company.
For further detailed information, please see the ad hoc announcement issued this morning. and the updated investor presentation. These documents are both available on our website at basilea.com.
Joining me presenting on the call today is Dr. Marc Engelhardt, our Chief Medical Officer. Also available to answer questions is Adesh
Basilea Pharmaceutica AG to Discuss the ERADICATE Topline Results Call Transcript
Mar 03, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers